358570.KQ
GI Innovation, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 7,620.00
−5.93%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.5B | 5.8B | 24.3M | 5.3B | 3.5B |
| Cost of Revenue | 2.3B | 3.0B | 3.1B | 3.3B | 3.2B |
| Gross Profit | 3.2B | 2.8B | (3.1B) | 2.0B | 343.0M |
| Operating Expenses | |||||
| R&D Expense | 38.5B | 34.1B | 34.3B | 42.4B | 58.4B |
| SG&A Expense | 6.0B | 3.9B | 2.7B | 15.1B | 67.7B |
| General & Admin Expense | 1.4B | 1.8B | 1.4B | 13.6B | 24.7B |
| Selling & Marketing Expense | 1.8B | 2.1B | 1.3B | 1.5B | 43.0B |
| Other Expenses | 4.2B | 6.5B | 8.5B | 13.8B | (55.4B) |
| Total Operating Expenses | 48.7B | 44.5B | 45.5B | 57.6B | 70.7B |
| Cost and Expenses | 50.9B | 47.5B | 48.3B | 60.9B | 73.9B |
| Operating Income (EBIT) | (45.4B) | (41.7B) | (48.6B) | (55.6B) | (70.4B) |
| Non-Operating | |||||
| Interest Income | 3.1B | 2.6B | 1.0B | 2.0B | 1.8B |
| Interest Expense | 672.0M | 1.6B | 988.5M | 362.4M | 388.8M |
| Net Interest Income | 2.5B | 1.1B | 29.9M | 1.6B | 1.4B |
| Other Non-Op Income/Expense | 6.3B | 6.5B | (10.7B) | 7.8B | 248.3M |
| Non-Operating Income (excl Interest) | (5.9B) | (6.9B) | 3.1B | (943.9M) | 9.1B |
| EBT (Pre-Tax Income) | (39.1B) | (35.1B) | (59.0B) | (47.8B) | (70.1B) |
| Income Tax Expense | — | 135.0M | (222.1M) | 473.1M | 9.7B |
| Bottom Line | |||||
| Net Income | (39.1B) | (35.1B) | (58.8B) | (55.5B) | (79.8B) |
| Earnings from Cont. Ops | (39.1B) | (35.1B) | (51.0B) | (55.5B) | (79.8B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (39.1B) | (35.1B) | (58.8B) | (55.5B) | (79.8B) |
| Per Share | |||||
| Basic EPS | (₩614) | (₩556) | (₩1,128) | (₩1,258) | (₩1,814) |
| Diluted EPS | (₩614) | (₩556) | (₩1,128) | (₩1,258) | (₩1,814) |
| Revenue Per Share | ₩85 | ₩93 | ₩0 | ₩121 | ₩80 |
| Shares | |||||
| Basic Shares Outstanding | 64.3M | 62.6M | 52.2M | 44.1M | 44.0M |
| Diluted Shares Outstanding | 64.3M | 62.6M | 52.2M | 44.1M | 44.0M |
| Profitability Metrics | |||||
| EBITDA | (53.8B) | (38.7B) | (54.9B) | (51.3B) | (66.6B) |
| D&A | 2.3B | 3.0B | 3.1B | 3.3B | 3.2B |
| EBIT | (43.6B) | (41.7B) | (48.3B) | (54.7B) | (69.7B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026